港股異動 | 和黃醫藥漲超5%,獲券商看高目標價至25.12港元
$和黃醫藥(00013.HK)$逆勢拉昇漲超5%,現報17.78港元,總市值153.76億港元。
華創證券首予和黃醫藥“推薦”評級,目標價25.12港元,核心產品療效優異,國際化潛力巨大。公司自主研發了13個抗腫瘤創新分子藥物,同時正在全球開展多項臨牀研究,包括15項註冊/潛在註冊研究,並且在中國建立了成熟商業化團隊,已覆蓋中國超過3000家腫瘤醫院。
此外,公司後續管線佈局全面,覆蓋血液瘤。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.